However, in this stratum, in the subgroup of indicated population undergoing thrombolysis or no reperfusion (i. e patients not undergoing primary PCI), the incidence of death/ re-MI at Day 30 was significantly reduced from 14.3 % on UFH to 11.5 % with fondaparinux (hazard ratio 0.79, 95 % CI, 0.64, 0.98, p = 0.03).
Vendar pa se je v tej podskupini pri bolnikih, pri katerih je bila izvedena tromboliza ali reperfuzija ni bila izvedena (to je bolniki pri katerih ni bila izvedena primarna PCI) smrtnost/ pojavnost re- MI do 30. dne pomembno zmanjšala s 14, 3 % pri UFH na 11, 5 % pri fondaparinuksu (razmerje tveganja 0, 79, 95 interval zaupanja, 0, 64; 0, 98, p = 0, 03).